 | Stefan Hans Hohnloser |
Prominent publications by Stefan Hans Hohnloser
BACKGROUND: In the AVERROES study, apixaban, a novel factor Xa inhibitor, reduced the risk of stroke or systemic embolism in patients with atrial fibrillation who were at high risk of stroke but unsuitable for vitamin K antagonist therapy. We aimed to investigate whether the subgroup of patients with previous stroke or transient ischaemic attack (TIA) would show a greater benefit from apixaban compared with aspirin than would patients without previous cerebrovascular events.
METHODS: In ...
| Also Ranks for: Atrial Fibrillation | patients stroke | apixaban aspirin | transient ischaemic attack | systemic embolism |
BACKGROUND: Many patients with atrial fibrillation are at high risk for stroke and require antithrombotic therapy. Antiarrhythmic drugs have not previously been shown to reduce the risk of stroke in atrial fibrillation. The effect of dronedarone, a new multichannel-blocking antiarrhythmic drug, on stroke has been evaluated in a randomized, double-blind clinical trial, ATHENA (A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg BID for the ...
| Also Ranks for: Cardiovascular Hospitalization | dronedarone patients | stroke atrial fibrillation | atrial flutter | antithrombotic therapy |
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
[ PUBLICATION ]
BACKGROUND: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial.
METHODS AND RESULTS: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. ...
| Also Ranks for: Warfarin Dabigatran | atrial fibrillation | younger patients | 2 doses | risk major bleeding |
BACKGROUND: Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrial fibrillation, but this therapy is associated with a high risk of bleeding.
METHODS: In this multicenter trial, we randomly assigned 2725 patients with atrial fibrillation who had undergone PCI to triple therapy with warfarin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin (for 1 to 3 months) ...
| Also Ranks for: Atrial Fibrillation | united states | dual therapy | pci risk | hazard ratio |
BACKGROUND: Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke. Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients.
METHODS: In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and ...
| Also Ranks for: Atrial Fibrillation | apixaban patients | year aspirin | hazard ratio | risk stroke |
BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.
METHODS: In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with ...
| Also Ranks for: Atrial Fibrillation | year apixaban | warfarin hazard ratio | rates death | stroke patients |
AIMS: After percutaneous coronary intervention (PCI) in patients with atrial fibrillation, safety and efficacy with dabigatran dual therapy were evaluated in pre-specified subgroups of patients undergoing PCI due to acute coronary syndrome (ACS) or elective PCI, and those receiving ticagrelor or clopidogrel treatment.
METHODS AND RESULTS: In the RE-DUAL PCI trial, 2725 patients were randomized to dabigatran 110 mg or 150 mg with P2Y12 inhibitor, or warfarin with P2Y12 inhibitor and ...
| Also Ranks for: Dual Therapy | atrial fibrillation | coronary intervention | patients acs | elective pci |
BACKGROUND: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in lower mortality. We assessed in this trial's participants how results differed according to patients' CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, used to predict the risk of stroke and bleeding.
METHODS: ARISTOTLE was a double-blind, ...
| Also Ranks for: Atrial Fibrillation | apixaban warfarin | risk stroke | secondary analysis | systemic embolism |
BACKGROUND: Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead. We investigated the hypothesis that the addition of clopidogrel to aspirin would reduce the risk of vascular events in patients with atrial fibrillation.
METHODS: A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom vitamin K-antagonist therapy was unsuitable were ...
| Also Ranks for: Atrial Fibrillation | clopidogrel aspirin | stroke patients | myocardial infarction | year relative risk |
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation
[ PUBLICATION ]
BACKGROUND: Renal impairment increases the risk of stroke and bleeding in patients with atrial fibrillation. In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, dabigatran, with ≈80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly less major bleeding in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation. This prespecified study investigated these ...
| Also Ranks for: Renal Function | atrial fibrillation | major bleeding patients | systemic embolism | dabigatran warfarin |
BACKGROUND: Thrombolysis has become the standard therapeutic approach in patients with acute myocardial infarction. To identify patients who may benefit from early invasive procedures, reliable noninvasive assessment of success or failure of thrombolytic therapy is mandatory.
METHODS AND RESULTS: In a prospective study in 63 consecutive patients undergoing thrombolysis for their first myocardial infarction, serial measurements of creatine kinase (CK), its isoenzyme CK-MB, myoglobin, and ...
| Also Ranks for: Creatine Kinase | myoglobin ck | coronary artery | 90 minutes | thrombolytic therapy |
OBJECTIVES: This study sought to assess the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial, and the treatment effect of apixaban according to NT-proBNP levels.
BACKGROUND: Natriuretic peptides are associated with mortality and cardiovascular events in several cardiac diseases.
METHODS: In the ARISTOTLE trial, ...
| Also Ranks for: Aristotle Trial | natriuretic peptide | apixaban warfarin | ntprobnp levels | stroke mortality |
OBJECTIVES: The aim of this study was to determine the risk of major clinical and thromboembolic events after cardioversion for atrial fibrillation in subjects treated with apixaban, an oral factor Xa inhibitor, compared with warfarin.
BACKGROUND: In patients with atrial fibrillation, thromboembolic events may occur after cardioversion. This risk is lowered with vitamin K antagonists and dabigatran.
METHODS: Using data from the ARISTOTLE (Apixaban for Reduction in Stroke and Other ...
| Also Ranks for: Atrial Fibrillation | thromboembolic events | patients cardioversion | schedule echocardiography | receiving warfarin |
IMPORTANCE: Renal impairment confers an increased risk of stroke, bleeding, and death in patients with atrial fibrillation. Little is known about the efficacy and safety of apixaban in relation to renal function changes over time.
OBJECTIVES: To evaluate changes of renal function over time and their interactions with outcomes during a median of 1.8 years of follow-up in patients with atrial fibrillation randomized to apixaban vs warfarin treatment.
DESIGN, SETTING, AND PARTICIPANTS: The ...
| Also Ranks for: Renal Function | patients atrial fibrillation | apixaban warfarin | systemic embolism | major bleeding |
IMPORTANCE: In the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 mg twice daily; patients with at least 2 dose-reduction criteria-80 years or older, weight 60 kg or less, and creatinine level 1.5 mg/dL or higher-received a reduced dose of apixaban of 2.5 mg twice daily. Little is known about patients with 1 dose-reduction criterion who received the 5 mg twice daily dose of ...
| Also Ranks for: Apixaban Patients | low body weight | advanced age | systemic embolism | major bleeding |
Stefan Hans Hohnloser: Influence Statistics
| Concept | World rank |
|---|---|
| positive mtwa | #1 |
| tachymyopathy patients | #1 |
| safety sotalol | #1 |
| new implantable device | #1 |
| 50 reentry | #1 |
| pore ic50 | #1 |
| 14 postinfarction patients | #1 |
| trial dronedarone | #1 |
| oac germany | #1 |
| dosages drug efficacy | #1 |
| disparity vr | #1 |
| tachymyopathy control population | #1 |
| prevention small studies | #1 |
| rate control life | #1 |
| proarrhythmic hazards | #1 |
| treatment sotalol | #1 |
| nonsustained lvef | #1 |
| patients suspected tachymyopathy | #1 |
| sinus rhythm control | #1 |
| atrial fibrillation hemorrhage | #1 |
| supraventricular arrhythmias device | #1 |
| dual singlecoil icd | #1 |
| clinical cardiology committee | #1 |
| ventureaf | #1 |
| patient sotalol | #1 |
| adjusted hrs warfarin | #1 |
| lower turnaround point | #1 |
| tedisamil antiarrhythmic drug | #1 |
| 102 consecutive patients | #1 |
| state 40 mv | #1 |
| 110 dual | #1 |
| metaanalysis rivaroxaban | #1 |
| apixaban 089 95 | #1 |
| proarrhythmic hazards agents | #1 |
| treatment noac starters | #1 |
| irat spontaneous restoration | #1 |
| defibrillator interventions patients | #1 |
| kcnh2r835q | #1 |
| qp patients | #1 |
| beta blockers benefit | #1 |
| patients gallopamil | #1 |
| rivaroxaban gastrointestinal bleeding | #1 |
| tachymyopathy patients wcd | #1 |
| icds mtwa testing | #1 |
| arrhythmogenic hazards | #1 |
| cardiology twa | #1 |
| model lvef | #1 |
| icd invasive testing | #1 |
| incidence time patients | #1 |
| ventricular tachycardia year | #1 |
Key People For Atrial Fibrillation
Stefan Hans Hohnloser:Expert Impact
Concepts for whichStefan Hans Hohnloserhas direct influence:Atrial fibrillation, Patients atrial fibrillation, Myocardial infarction, Sinus rhythm, Catheter ablation, Heart failure, Cardiac death, Renal function.
Stefan Hans Hohnloser:KOL impact
Concepts related to the work of other authors for whichfor which Stefan Hans Hohnloser has influence:Atrial fibrillation, Heart failure, Catheter ablation, Oral anticoagulants, Myocardial infarction, Stroke prevention, Major bleeding.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |